YCYing Chen

Ying Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ying Chen has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    IMRT Images Based on Swarm Intelligence Algorithm in the Treatment of Nasopharyngeal Carcinoma and Pain

    by Xiaoli Fu, Minxiang Li, Mantian Yin, Qing Li, Ying Chen

    Objective. To investigate the IMRT treatment of nasopharyngeal carcinoma term effect, toxicity, and technical features. Methods. Sliding windows dynamic CT image-guided IMRT techniques on 31 patients for treatment of nasopharyngeal carcinoma radical radiotherapy, with 30 to 33min irradiation. Target prescription dose GTVnx, GTVnd, CTV1, and CTV2 were 7076Gy, 6870Gy, 6066Gy, and 54Gy, while giving a dose of vital organs, the brain stem, and other restrictions to protect the parotid gland. Results. During 3 to 18 months of follow-up for a median period of 10 months, 1-year locoregional patients progression-free survival, distant metastasis-free survival, and overall survival rates were 93.5, 87.1, and 93.5, respectively. Acute radiation reactions of grade I and II, xerostomia, and radioactive stomatitis were not observed. IMRT DVH analysis showed increased total dose and the irradiation target volume divided doses, reduced OARs illuminated, and the total dose divided doses. Conclusion. Intensity-modulated radiation therapy can achieve good short-term effects, significantly reduce the acute radiation response, and improve the quality of life of patients. It is worthy of promotion and application and in-depth research.


  • Open Access

    Phase II Study of Adjuvant Chemoradiotherapy Using Docetaxel/Cisplatin/5-Fluorouracil Before and After Intensity-modulated Radiotherapy With Concurrent Docetaxel in Patients With Completely (R0) Resected Gastric Carcinoma

    by Yong Liu, Guoqi Zhao, Yi Xu, Tiening Zhang, Zhixiao Chen, Ge Yan, Wenzhi Tu, Ye Hu, Ying Chen, Xia He, et al.

    The Intergroup 0116 study has demonstrated a significant survival benefit for completely resected (R0) gastric cancer patients treated with a fluorouracil/leucovorin chemoradiotherapy regimen. However, this regimen is also toxic and less effective in terms of distant disease control. Therefore, a more efficacious and safer regimen is urgently needed. Patients with R0 resected gastric carcinoma received up to two 21-day cycles of postoperative adjuvant preradiation and postradiation DCF chemotherapy (docetaxel 37.5 mg/m2 on days 1 and 8, cisplatin 25 mg/m2 on days 1 to 3, and a continuous infusion of fluorouracil 750 mg/m2 on days 1 to 5), respectively. Chemoradiotherapy between preradiation and postradiation chemotherapy was initiated on day 43 and consisted of intensity-modulated radiotherapy (45 Gy) plus concurrent docetaxel 20 mg/m2 weekly for 5 weeks. A total of 55 patients were evaluated and 76% (42) of patients completed the prescribed therapy. With a median follow-up of 61 months, the 3- and 5-year progression-free survival rates were 67% (95% confidence interval [CI], 54%-80%) and 59% (95% CI, 46%-72%), respectively; and the 3- and 5-year overall survival rates were 72% (95% CI, 60%-84%) and 61% (95% CI, 48%-74%), respectively. The most common grade 3 or greater toxicity, during the chemotherapy phase, was neutropenia (24%). Common grade 3/4 toxicities during concurrent chemoradiotherapy were nausea (32%), vomiting (26%), fatigue (15%), and anorexia (19%). These results demonstrate that this adjuvant regimen is active with an acceptable toxicity profile. A randomized phase 3 trial comparing the Intergroup 0116 chemoradiotherapy regimen with this regimen is underway. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/